Condition

Prostatic Neoplasms clinical trials and research

• 37Clinical trials
• 1New in 30 days
• 49Countries

Newest Prostatic Neoplasms clinical trials

All recruiting trials (37)

• JNJ-101556143 plus Best Supportive Care for metastatic prostate cancer

  This study tests whether adding JNJ-101556143 to standard supportive care helps people with metastatic, hormone-resistant prostate cancer live longer than those who receive placebo plus supportive care.

  Recruiting at 4 sites Phase 3 Janssen Research & Development, LLC · El Paso, Texas and 3 other locations · NCT07906717

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Testing JNJ-101556143 in men with advanced prostate cancer that no longer responds to hormone therapy

  This study tests JNJ-101556143 in men with metastatic, hormone-resistant prostate cancer to see if tumors shrink or disappear.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Largo, Florida and 13 other locations · NCT07832292

• New treatment option for advanced prostate cancer using JNJ-98768111

  A first-in-human study tests JNJ-98768111 to see how safe it is and find the best dose for people with advanced prostate cancer who have already tried other therapies.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07746713

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• Low-to-moderate load power and strength training for men with metastatic prostate cancer

  This trial will test whether a twice-weekly, supervised low-to-moderate load power training program can improve fitness and quality of life for men with metastatic prostate cancer who are on androgen deprivation therapy.

  Recruiting University of Alicante · San Vicent del Raspeig, Alicante · NCT07572760

• Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer

  This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.

  Recruiting CHU de Quebec-Universite Laval · Gatineau, Quebec and 3 other locations · NCT07483658

• Tracking apalutamide use in men with metastatic hormone-sensitive prostate cancer in France

  This project will see if men with metastatic hormone-sensitive prostate cancer in France take apalutamide as prescribed during their first year of treatment.

  Recruiting Janssen Cilag S.A.S. · Caen · NCT07451002

• Acupuncture to ease hot flashes in men on hormone therapy for prostate cancer

  This trial will test if weekly acupuncture plus lifestyle education can help reduce hot flashes and related symptoms in men receiving androgen deprivation therapy for prostate cancer.

  Recruiting Inova Health Care Services · Fairfax, Virginia · NCT07335224

• Pasritamig plus JNJ-86974680 for advanced prostate cancer

  This trial will test whether combining pasritamig with JNJ-86974680 is safe and to find the best dose for people with metastatic castration-resistant prostate cancer.

  Recruiting at 5 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 4 other locations · NCT07319871

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• Combination treatment with JNJ-78278343 and JNJ-95298177 for prostate cancer

  This trial tests whether giving two experimental drugs together, JNJ-78278343 and JNJ-95298177, is safe and tolerable for men with metastatic castration-resistant prostate cancer.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07082920

• New treatment for metastatic prostate cancer using ifinatamab deruxtecan

  This study is testing a new treatment called ifinatamab deruxtecan to see if it helps men with advanced prostate cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 290 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 302 other locations · NCT06925737

• Dual-nuclide PET/CT imaging to test simultaneous tracer separation in cancer patients and healthy volunteers

  This study tests a simultaneous dual-tracer PET/CT imaging method in prostate cancer, neuroendocrine tumors, glioma, lung cancer patients, and healthy volunteers to see if it can accurately separate and measure two tracers in humans.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT06914427

• Evaluating genomic testing and radiotherapy for prostate cancer recurrence

  This study is testing if a genomic test can help guide radiation treatment for men whose prostate cancer comes back after surgery.

  Recruiting Regina Elena Cancer Institute · Roma · NCT06894628

• Testing DM002 in patients with advanced solid tumors

  This study is testing a new drug called DM002 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 7 sites Phase 1/2 Doma Biopharmaceutical（Suzhou）Co., Ltd. · San Francisco, California and 6 other locations · NCT06751329

• Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy

  This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.

  Recruiting Phase 4 VA Greater Los Angeles Healthcare System · Los Angeles, California · NCT06706921

• Adaptive radiation for prostate cancer

  This study tests whether daily adaptive radiotherapy led by radiation therapists, with the option to use smaller treatment margins, can reduce side effects for men having prostate radiotherapy.

  Recruiting Royal North Shore Hospital · St Leonards, New South Wales · NCT06547398

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

• Comparing Opevesostat to Other Hormonal Treatments for Advanced Prostate Cancer

  This study tests if a new treatment called opevesostat, combined with hormone therapy, can help men with advanced prostate cancer live longer and feel better compared to other hormonal treatments they might have already tried.

  Recruiting at 297 sites Phase 3 Merck Sharp & Dohme LLC · Tucson, Arizona and 329 other locations · NCT06136650

• Combination treatment for advanced prostate cancer

  This study is testing a combination of two new drugs to see if they are safe and how well they work for people with advanced prostate cancer that hasn't responded to other treatments.

  Recruiting at 22 sites Phase 1 Janssen Research & Development, LLC · Aurora, Colorado and 21 other locations · NCT06095089

• Using 64Cu-SAR-bisPSMA PET to detect prostate cancer spread before surgery

  This study is testing a new imaging method to see if it can help find prostate cancer spread in high-risk patients before they have surgery.

  Recruiting at 34 sites Phase 3 Clarity Pharmaceuticals Ltd · Birmingham, Alabama and 33 other locations · NCT06056830

• Exercise program to slow prostate cancer progression in Black men

  This study is testing whether a 16-week exercise program can help Black men with early-stage prostate cancer slow down the progression of their disease.

  Recruiting Fred Hutchinson Cancer Center · Boston, Massachusetts and 3 other locations · NCT05918263

• Focal dose escalation for localized prostate cancer treatment

  This study is testing a new way to treat localized prostate cancer by giving higher doses of radiation in a shorter time while also using hormone therapy to see if it works better and causes fewer side effects.

  Recruiting Phase 2 Ottawa Hospital Research Institute · Ottawa, Ontario · NCT05851547

• Comparing two prostate cancer treatments for quality of life

  This study is testing whether two prostate cancer treatments, Relugolix and Leuprolide, can help improve the quality of life for men with localized or recurring prostate cancer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05765500

• Focal therapy using SBRT for single prostate tumors

  This study is testing whether a targeted radiation treatment can effectively shrink single prostate tumors in men with localized prostate cancer while causing fewer side effects than standard treatments.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05616650

• Evaluating MRI and biopsy methods for prostate cancer detection

  This study is testing whether a new type of MRI and a different way to do biopsies can help find prostate cancer more accurately in men who might have it.

  Recruiting at 14 sites Imperial College London · Southend-on-Sea, Essex and 14 other locations · NCT05574647

• Treatment for advanced prostate cancer using Lutetium-177

  This study is testing a new treatment using Lutetium-177 for men with advanced prostate cancer that hasn't responded to other therapies to see how safe it is and how well it works.

  Recruiting at 20 sites Phase 1/2 Blue Earth Therapeutics Ltd · Miami, Florida and 20 other locations · NCT05413850

• Understanding lymphedema after urologic surgery

  This study looks at how often and how badly lymphedema affects people after they have surgery for urologic cancer that involves removing lymph nodes.

  Recruiting at 2 sites Vastra Gotaland Region · Gothenburg and 1 other locations · NCT05264337

• Effect of testosterone therapy on outcomes after prostate surgery

  This study is testing if testosterone therapy can help men with low testosterone feel better and improve their quality of life after prostate cancer surgery.

  Recruiting at 10 sites Phase 3 Canisius-Wilhelmina Hospital · Amsterdam and 9 other locations · NCT04833426

• Monitoring prostate health in men with high genetic risk for prostate cancer

  This study is trying to see how the prostate health of men aged 30-75 with certain genetic changes linked to a higher risk of prostate cancer changes over time.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03805919

• Database of prostate cancer patients at Institut Paoli-Calmettes

  This study is creating a detailed database of prostate cancer patients to help researchers and doctors understand the disease better and improve treatment outcomes.

  Recruiting Institut Paoli-Calmettes · Marseille, Bouches-du Rhône · NCT02869594

• Comparing surgery and radiotherapy for advanced prostate cancer

  This study is testing if surgery combined with radiation can help men with advanced prostate cancer live longer compared to just using radiation and hormone therapy.

  Recruiting at 29 sites Karolinska University Hospital · Aalborg and 29 other locations · NCT02102477

• Using imaging to assess prostate cancer response to radiation therapy

  This study is testing advanced imaging techniques to see how well radiation therapy works for men with prostate cancer and if it can help identify those who might need more treatment.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01834001

• Collecting blood samples from prostate cancer patients

  This study is collecting blood samples from men with prostate cancer to see if genetic differences affect how the disease progresses.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00923221

• Monitoring prostate cancer in men choosing active surveillance

  This study is trying to find out if certain markers can help tell the difference between aggressive and less serious prostate cancers in men who are choosing to monitor their condition instead of starting treatment right away.

  Recruiting at 11 sites University of Washington · San Francisco, California and 10 other locations · NCT00756665

Related topics

Quick answers

How many Prostatic Neoplasms clinical trials are recruiting right now?

37, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 49 countries. The most sites are in United States (20 trials), Australia (7 trials), France (6 trials), China (5 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1: 5, Phase 3: 5, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →